TrialVaccine2023

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.

Eline A Feitsma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.